(株)ミズホメディーの貸借残高情報
| 主市場 | 業種 | 証券コード/EDINET | 英名称 |
|---|
| 東証STD | 医薬品 | 4595/ - | - |
| 公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
|---|
| 2017/08/18 | 日証協 | 112,000株 | -10.9% | 21,200株 | +175.32% | 212,192株 | +1.6% | 29,244株 | +306.17% |
| 2017/08/10 | 日証協 | 125,700株 | +1.7% | 7,700株 | -9.41% | 208,848株 | +0.87% | 7,200株 | +1.41% |
| 2017/08/04 | 日証協 | 123,600株 | +2.06% | 8,500株 | +117.95% | 207,048株 | +0.54% | 7,100株 | +173.08% |
| 2017/07/28 | 日証協 | 121,100株 | -6.34% | 3,900株 | -89.2% | 205,943株 | -1.15% | 2,600株 | -65.33% |
| 2017/07/21 | 日証協 | 129,300株 | +16.49% | 36,100株 | -37.11% | 208,343株 | +5.31% | 7,500株 | -26.05% |
| 2017/07/14 | 日証協 | 111,000株 | -5.92% | 57,400株 | -54.26% | 197,847株 | -2.63% | 10,142株 | -94.21% |
| 2017/07/07 | 日証協 | 117,984株 | +47.11% | 125,500株 | +41.83% | 203,199株 | +799.11% | 175,224株 | +421.5% |
| 2017/06/30 | 日証協 | 80,200株 | +28.12% | 88,484株 | +1020.05% | 22,600株 | -49.73% | 33,600株 | +380% |
| 2017/06/23 | 日証協 | 62,600株 | +3.64% | 7,900株 | +14.49% | 44,957株 | -58.27% | 7,000株 | -89.69% |
| 2017/06/16 | 日証協 | 60,400株 | 0% | 6,900株 | -73.66% | 107,727株 | +128.58% | 67,900株 | +2724.46% |
| 2017/06/09 | 日証協 | 60,400株 | -38.05% | 26,200株 | -33.84% | 47,128株 | -24.02% | 2,404株 | -67.51% |
| 2017/06/02 | 日証協 | 97,499株 | +52.34% | 39,600株 | -33.22% | 62,026株 | +27.03% | 7,400株 | -80.37% |
| 2017/05/26 | 日証協 | 64,000株 | +12.08% | 59,299株 | +282.57% | 48,826株 | +9.17% | 37,703株 | +479.87% |
| 2017/05/19 | 日証協 | 57,100株 | +8.14% | 15,500株 | -14.36% | 44,725株 | +8.22% | 6,502株 | +80.06% |
| 2017/05/12 | 日証協 | 52,800株 | +6.45% | 18,100株 | +3520% | 41,327株 | +2.43% | 3,611株 | 0% |
| 2017/05/02 | 日証協 | 49,600株 | +1.43% | 500株 | -94.32% | 40,346株 | +2.23% | 0株 | -100% |
| 2017/04/28 | 日証協 | 48,900株 | +10.63% | 8,800株 | -30.16% | 39,466株 | +7.64% | 2,500株 | -52.83% |
| 2017/04/21 | 日証協 | 44,200株 | +26.29% | 12,600株 | +65.79% | 36,666株 | +19.95% | 5,300株 | -20.9% |
| 2017/04/14 | 日証協 | 35,000株 | -31.64% | 7,600株 | -75% | 30,569株 | -13.53% | 6,700株 | -39.17% |
※株式分割は考慮していませんのでご注意ください。
Page Top